CART Archives

FDA Panel Votes to Support CAR-T Therapies by Johnson & Johnson and Bristol Myers Squibb for Multiple Myeloma Treatment

Silver Spring, Maryland – An FDA advisory committee voted overwhelmingly in favor of recommending the approval of CAR-T therapies from Johnson & Johnson, Legend Biotech, Bristol Myers Squibb, and 2seventyBio for the treatment of multiple myeloma. The committee’s support for these therapies highlights a significant milestone in the ongoing discussions surrounding the use of CAR-T treatments in cancer care. During the committee meeting, concerns were raised about the higher rate of early deaths observed in …

New Concerns Arise Over Early Deaths in CAR-T Myeloma Trials with Carvykti and Abecma

Washington, D.C. – The Food and Drug Administration (FDA) has raised concerns about early deaths in clinical trials for CAR-T therapies used to treat multiple myeloma. Specifically, the FDA flagged the experimental treatments Carvykti from J&J and Legend, as well as Abecma from Bristol Myers Squibb. During the trials, patients receiving these CAR-T therapies experienced unexpected deaths, prompting the FDA to issue a warning. While CAR-T therapies have shown promising results in treating certain types …